Inhibrx Biosciences, Inc. (INBX)
NASDAQ·Healthcare·Biotechnology
$129.92
-1.16%
Mkt Cap $1.75B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 19, 2026 | $1.11M | — | — | -$2.08 | -$2.11 | -1.44% | — | — |
| Q4 2025 Nov 14, 2025 | — | — | — | -$2.08 | -$2.28 | -9.62% | — | — |
| Q3 2025 Aug 13, 2025 | — | $1.30M | — | -$2.92 | -$1.85 | +36.64% | — | — |
| Q2 2025 May 14, 2025 | — | — | — | -$2.55 | -$2.80 | -9.80% | — | — |
| Q1 2025 Mar 17, 2025 | — | $100.00K | — | -$2.88 | -$3.09 | -7.29% | — | — |
| Q4 2024 Nov 14, 2024 | — | — | — | -$3.06 | -$2.84 | +7.19% | — | — |
| Q3 2024 Aug 13, 2024 | — | $100.00K | — | -$3.60 | $125.48 | +3585.56% | — | — |
| Q2 2024 Jun 3, 2024 | $50.00K | — | — | -$1.04 | -$1.44 | -38.46% | — | — |
| Q1 2024 Feb 28, 2024 | $50.00K | $1.63M | +3168.00% | -$1.07 | -$1.73 | -61.68% | — | — |
| Q4 2023 Nov 9, 2023 | $50.00K | $119.00K | +138.00% | -$1.01 | -$1.10 | -8.91% | — | — |
| Q3 2023 Aug 7, 2023 | — | $30.00K | — | -$1.02 | -$1.08 | -5.88% | — | — |
| Q2 2023 May 8, 2023 | $150.00K | $17.00K | -88.67% | -$0.84 | -$1.12 | -33.33% | — | — |
| Q1 2023 Mar 6, 2023 | $994.00K | $274.00K | -72.43% | -$0.80 | -$0.95 | -18.75% | — | — |
| Q4 2022 Nov 7, 2022 | $633.33K | $278.00K | -56.11% | -$1.01 | -$0.90 | +10.89% | — | — |
| Q3 2022 Aug 8, 2022 | $1.07M | $711.00K | -33.50% | -$0.84 | -$0.97 | -15.48% | — | — |
| Q2 2022 May 9, 2022 | $1.10M | $915.00K | -17.01% | -$0.62 | -$0.80 | -29.03% | — | — |
| Q1 2022 Feb 28, 2022 | $1.21M | $2.84M | +134.70% | -$0.53 | -$0.55 | -3.77% | — | — |
| Q4 2021 Nov 9, 2021 | $1.50M | $2.51M | +67.20% | -$0.57 | -$0.54 | +5.26% | — | — |
| Q3 2021 Aug 9, 2021 | $820.00K | $918.00K | +11.95% | -$0.51 | -$0.55 | -7.84% | — | — |
| Q2 2021 May 13, 2021 | $1.01M | $863.00K | -14.52% | -$0.61 | -$0.51 | +16.39% | — | — |